|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ,
Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics,
2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen HN, Yuan K, Xie N, Wang K, Huang Z,
Chen Y, Dou Q, Wu M, Nice EC, Zhou ZG, et al: PDLIM1 stabilizes the
E-cadherin/β-catenin complex to prevent epithelial-mesenchymal
transition and metastatic potential of colorectal cancer cells.
Cancer Res. 76:1122–1134. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun J, Ding C, Yang Z, Liu T, Zhang X,
Zhao C and Wang J: The long non-coding RNA TUG1 indicates a poor
prognosis for colorectal cancer and promotes metastasis by
affecting epithelial-mesenchymal transition. J Transl Med.
14:422016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Agarwal E, Robb CM, Smith LM, Brattain MG,
Wang J, Black JD and Chowdhury S: Role of Akt2 in regulation of
metastasis suppressor 1 expression and colorectal cancer
metastasis. Oncogene. 36:3104–3118. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nürnberg A, Kitzing T and Grosse R:
Nucleating actin for invasion. Nat Rev Cancer. 11:177–187. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xie R, Wang J, Tang W, Li Y, Peng Y, Zhang
H, Liu G, Huang X, Zhao J, Li A, et al: Rufy3 promotes metastasis
through epithelial-mesenchymal transition in colorectal cancer.
Cancer Lett. 390:30–38. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fu Y, Zheng S, An N, Athanasopoulos T,
Popplewell L, Liang A, Li K, Hu C and Zhu Y: β-catenin as a
potential key target for tumor suppression. Int J Cancer.
129:1541–1551. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Valenta T, Hausmann G and Basler K: The
many faces and functions of β-catenin. EMBO J. 31:2714–2736. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cai J, Guan H, Fang L, Yang Y, Zhu X, Yuan
J, Wu J and Li M: MicroRNA-374a activates Wnt/β-catenin signaling
to promote breast cancer metastasis. J Clin Invest. 123:566–579.
2013.PubMed/NCBI
|
|
11
|
Liu C, Li Y, Semenov M, Han C, Baeg GH,
Tan Y, Zhang Z, Lin X and He X: Control of beta-catenin
phosphorylation/degradation by a dual-kinase mechanism. Cell.
108:837–847. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Brabletz T, Jung A, Reu S, Porzner M,
Hlubek F, Kunz-Schughart LA, Knuechel R and Kirchner T: Variable
beta-catenin expression in colorectal cancers indicates tumor
progression driven by the tumor environment. Proc Natl Acad Sci
USA. 98:10356–10361. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Höglund M, Frigyesi A, Säll T, Gisselsson
D and Mitelman F: Statistical behavior of complex cancer
karyotypes. Genes Chromosomes Cancer. 42:327–341. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Carvalho FL, Marchionni L, Gupta A,
Kummangal BA, Schaeffer EM, Ross AE and Berman DM: HES6 promotes
prostate cancer aggressiveness independently of Notch signalling. J
Cell Mol Med. 19:1624–1636. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Swearingen ML, Sun D, Bourner M and
Weinstein EJ: Detection of differentially expressed HES-6 gene in
metastatic colon carcinoma by combination of suppression
subtractive hybridization and cDNA library array. Cancer Lett.
198:229–239. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ramos-Montoya A, Lamb AD, Russell R,
Carroll T, Jurmeister S, Galeano-Dalmau N, Massie CE, Boren J, Bon
H, Theodorou V, et al: HES6 drives a critical AR transcriptional
programme to induce castration-resistant prostate cancer through
activation of an E2F1-mediated cell cycle network. EMBO Mol Med.
6:651–61. 2014.PubMed/NCBI
|
|
17
|
Chiaramonte R, Colombo M, Bulfamante G,
Falleni M, Tosi D, Garavelli S, De Simone D, Vigolo E, Todoerti K,
Neri A, et al: Notch pathway promotes ovarian cancer growth and
migration via CXCR4/SDF1α chemokine system. Int J Biochem Cell
Biol. 66:134–140. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gramantieri L, Giovannini C, Lanzi A,
Chieco P, Ravaioli M, Venturi A, Grazi GL and Bolondi L: Aberrant
Notch3 and Notch4 expression in human hepatocellular carcinoma.
Liver Int. 27:997–1007. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Koyano-Nakagawa N, Kim J, Anderson D and
Kintner C: Hes6 acts in a positive feedback loop with the
neurogenins to promote neuronal differentiation. Development.
127:4203–4216. 2000.PubMed/NCBI
|
|
20
|
Bae S, Bessho Y, Hojo M and Kageyama R:
The bHLH gene Hes6, an inhibitor of Hes1, promotes neuronal
differentiation. Development. 127:2933–2943. 2000.PubMed/NCBI
|
|
21
|
Drenzek JG, Seiler NL, Jaskula-Sztul R,
Rausch MM and Rose SL: Xanthohumol decreases Notch1 expression and
cell growth by cell cycle arrest and induction of apoptosis in
epithelial ovarian cancer cell lines. Gynecol Oncol. 122:396–401.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Benson AB III, Arnoletti JP, Bekaii-Saab
T, Chan E, Chen YJ, Choti MA, Cooper HS, Dilawari RA, Engstrom PF,
Enzinger PC, et al: National Comprehensive Cancer Network: Anal
Carcinoma, Version 2.2012: Featured updates to the NCCN guidelines.
J Natl Compr Canc Netw. 10:449–454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−∆∆C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wang L, Ouyang F, Liu X, Wu S, Wu HM, Xu
Y, Wang B, Zhu J, Xu X and Zhang L: Overexpressed CISD2 has
prognostic value in human gastric cancer and promotes gastric
cancer cell proliferation and tumorigenesis via AKT signaling
pathway. Oncotarget. 7:3791–3805. 2016.PubMed/NCBI
|
|
25
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES, et al: Gene set enrichment analysis: A
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mootha VK, Lindgren CM, Eriksson KF,
Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E,
Ridderstråle M, Laurila E, et al: PGC-1alpha-responsive genes
involved in oxidative phosphorylation are coordinately
downregulated in human diabetes. Nat Genet. 34:267–273. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Malone CMP, Domaschenz R, Amagase Y,
Dunham I, Murai K and Jones PH: Hes6 is required for actin
cytoskeletal organization in differentiating C2C12 myoblasts. Exp
Cell Res. 317:1590–1602. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nam SM, Kim YN, Kim JW, Kyeong DS, Lee SH,
Son Y, Shin JH, Kim J, Yi SS, Yoon YS, et al: Hairy and enhancer of
split 6 (Hes6) deficiency in mouse impairs neuroblast
differentiation in dentate gyrus without affecting cell
proliferation and integration into mature neurons. Cell Mol
Neurobiol. 36:57–67. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Haapa-Paananen S, Kiviluoto S, Waltari M,
Puputti M, Mpindi JP, Kohonen P, Tynninen O, Haapasalo H, Joensuu
H, Perälä M, et al: HES6 gene is selectively overexpressed in
glioma and represents an important transcriptional regulator of
glioma proliferation. Oncogene. 31:1299–1310. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wickramasinghe CM, Domaschenz R, Amagase
Y, Williamson D, Missiaglia E, Shipley J, Murai K and Jones PH:
HES6 enhances the motility of alveolar rhabdomyosarcoma cells. Exp
Cell Res. 319:103–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hartman J, Lam EW, Gustafsson JA and Ström
A: Hes-6, an inhibitor of Hes-1, is regulated by 17 beta-estradiol
and promotes breast cancer cell proliferation. Breast Cancer Res.
11:R792009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kuipers EJ, Grady WM, Lieberman D,
Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ and Watanabe T:
Colorectal cancer. Nat Rev Dis Primers. 1:150652015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhan T, Rindtorff N and Boutros M: Wnt
signaling in cancer. Oncogene. 36:1461–1473. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Okada-Iwasaki R, Takahashi Y, Watanabe Y,
Ishida H, Saito J, Nakai R and Asai A: The discovery and
characterization of K-756, a novel Wnt/β-catenin pathway inhibitor
targeting tankyrase. Mol Cancer Ther. 15:1525–1534. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Banday MZ, Sameer AS, Mir AH, Mokhdomi TA,
Chowdri NA and Haq E: Matrix metalloproteinase (MMP) −2, −7 and −9
promoter polymorphisms in colorectal cancer in ethnic Kashmiri
population - A case-control study and a mini review. Gene.
589:81–89. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Komiya Y, Onodera Y, Kuroiwa M, Nomimura
S, Kubo Y, Nam JM, Kajiwara K, Nada S, Oneyama C, Sabe H, et al:
The Rho guanine nucleotide exchange factor ARHGEF5 promotes tumor
malignancy via epithelial-mesenchymal transition. Oncogenesis.
5:e2582016. View Article : Google Scholar : PubMed/NCBI
|
